Spots Global Cancer Trial Database for biliary tract cancer
Every month we try and update this database with for biliary tract cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy | NCT02350686 | Biliary Tract C... | capecitabine oxaliplatin | 18 Years - | Samsung Medical Center | |
| Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer | NCT05239169 | Biliary Tract C... Intrahepatic Ch... Hilar Cholangio... Distal Cholangi... Gall Bladder Ca... | Durvalumab Tremelimumab Capecitabine | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer | NCT04677504 | Biliary Tract C... | Atezolizumab Bevacizumab Placebo Cisplatin Gemcitabine | 18 Years - | Hoffmann-La Roche | |
| Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing | NCT05520788 | Hepatocellular ... Biliary Tract C... | precise medicin... | 18 Years - | Tongji Hospital | |
| GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer | NCT05998447 | Biliary Tract C... | GEN-001 Pembrolizumab mFOLFOX | 19 Years - | Genome & Company | |
| A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours | NCT04969835 | Pancreatic Canc... Colorectal Canc... Non-small Cell ... Head and Neck C... Cancer of Unkno... Ovarian Cancer Breast Cancer Soft Tissue Sar... Bladder Cancer Oesophageal Can... Prostate Cancer Biliary Tract C... | AVA6000 | 18 Years - | Avacta Life Sciences Ltd | |
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | NCT04660929 | HER2-positive Adenocarcinoma Bile Duct Cance... Biliary Tract C... Bladder Cancer Breast Cancer Breast Neoplasm Carcinoma, Duct... Carcinoma, Hepa... Cancer Lung Cancer, No... Carcinoma, Ovar... Carcinoma, Smal... Carcinoma, Squa... Carcinoma, Tran... Colorectal Canc... Esophagogastric... Inflammatory Br... Stomach Neoplas... Malignant Neopl... Ovarian Neoplas... Pancreatic Canc... HER2-positive S... HER2-positive B... HER2-positive G... HER-2 Protein O... HER-2 Gene Ampl... Prostate Cancer Head and Neck C... Endometrial Can... Lung Cancer, Sm... | CT-0508 Pembrolizumab | 18 Years - | Carisma Therapeutics Inc | |
| A Study of the Efficacy and Safety of Chemotherapy Combined With Toripalimab in Advanced Biliary Tract Cancer | NCT03796429 | Biliary Tract C... | GS+Toripalimab | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours | NCT04969835 | Pancreatic Canc... Colorectal Canc... Non-small Cell ... Head and Neck C... Cancer of Unkno... Ovarian Cancer Breast Cancer Soft Tissue Sar... Bladder Cancer Oesophageal Can... Prostate Cancer Biliary Tract C... | AVA6000 | 18 Years - | Avacta Life Sciences Ltd | |
| A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer | NCT04692051 | Biliary Tract C... | Nab-paclitaxel ... Gemcitabine + C... | 18 Years - 70 Years | Huazhong University of Science and Technology | |
| Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC Immunotherapy | NCT06074029 | Biliary Tract C... Immune Checkpoi... Predictive Canc... | Immune Checkpoi... | 18 Years - 80 Years | Peking Union Medical College Hospital | |
| Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers | NCT02720601 | Biliary Tract C... | Irinotecan & Ca... | 18 Years - | New Mexico Cancer Care Alliance | |
| Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder | NCT05512377 | Pancreatic Neop... Solid Tumors Biliary Tract C... Lung Neoplasms Bladder Cancer | brigimadlin | 18 Years - | Boehringer Ingelheim | |
| Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC | NCT02992340 | Biliary Tract C... | Varlitinib Cisplatin Gemcitabine | - | ASLAN Pharmaceuticals | |
| A Clinical Study of MK-2870 Alone or With Chemotherapy to Treat Gastrointestinal Cancers (MK-9999-02A) | NCT06428409 | Colorectal Canc... Pancreatic Duct... Biliary Tract C... | Sacituzumab tir... Fluorouracil (5... Leucovorin (LV)... | 18 Years - | Merck Sharp & Dohme LLC | |
| Effect of PVE on Surgical Outcomes and Long-term Survival in Perihilar Cholangiocarcinoma | NCT06222619 | Biliary Tract C... Portal Vein Emb... | Potal vein embi... | - | Seoul National University Hospital | |
| RFA Combined With Chemotherapy for Unresectable Cholangiocarcinoma | NCT05028439 | Cholangiocarcin... | radiofrequency ... Chemotherapy dr... | 18 Years - 75 Years | First People's Hospital of Hangzhou | |
| Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer | NCT03818997 | Esophageal Canc... Biliary Tract C... GastroEsophagea... Hepatobiliary N... | DKN-01 Atezolizumab Paclitaxel | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Vessel Resection and Reconstruction of Biliary Tract Cancers | NCT01861483 | Biliary Tract C... | - | Kansai Hepatobiliary Oncology Group | ||
| Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers | NCT06001658 | Pancreatic Canc... | Gemcitabine Cisplatin Pembrolizumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer | NCT04677504 | Biliary Tract C... | Atezolizumab Bevacizumab Placebo Cisplatin Gemcitabine | 18 Years - | Hoffmann-La Roche | |
| A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | NCT03929666 | HER2-expressing... | ZW25 (Zanidatam... Capecitabine Cisplatin Fluorouracil Leucovorin Oxaliplatin Bevacizumab Gemcitabine | 18 Years - | Jazz Pharmaceuticals | |
| Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI | NCT05835778 | Biliary Tract C... | - | AstraZeneca | ||
| FOLFIRINOX for 2nd-line Treatment of BTC | NCT03778593 | Biliary Tract C... | 5-Fluorouracil Leucovorin Irinotecan Oxaliplatin 5% dextrose wat... | 20 Years - | Dong-A University Hospital | |
| Second Line Therapy in Advanced Biliary Tract Cancer | NCT01530503 | Biliary Tract C... | capecitabine an... Capecitabine | 18 Years - 75 Years | IRCCS San Raffaele | |
| FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study | NCT03110510 | Biliary Tract C... | Fluorouracil Irinotecan Hydr... leucovorin calc... | 20 Years - | Samsung Medical Center | |
| Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients | NCT03924466 | Metastatic Brea... Locally Advance... Cancer of Pancr... Solid Tumor Wit... Salivary Gland ... Gastric Cancer Endometrial Can... Uterine Cancer Non Small Cell ... Biliary Tract C... Cholangiocarcin... Colorectal Canc... Urothelial Carc... Prostate Cancer | 68GaNOTA-Anti-H... | 18 Years - | Universitair Ziekenhuis Brussel | |
| A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTC | NCT01267344 | Cholangiocarcin... Adenocarcinoma ... | gemcitabine, ox... cetuximab, gemc... | 20 Years - | National Health Research Institutes, Taiwan | |
| A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors | NCT06024174 | Advanced Solid ... | BMS-986466 Adagrasib Cetuximab | 18 Years - | Bristol-Myers Squibb | |
| Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer | NCT04642664 | Biliary Tract C... Cholangiocarcin... Biomarker Hepatobiliary N... | Apatinib plus C... | 18 Years - | Peking Union Medical College Hospital | |
| Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients | NCT03924466 | Metastatic Brea... Locally Advance... Cancer of Pancr... Solid Tumor Wit... Salivary Gland ... Gastric Cancer Endometrial Can... Uterine Cancer Non Small Cell ... Biliary Tract C... Cholangiocarcin... Colorectal Canc... Urothelial Carc... Prostate Cancer | 68GaNOTA-Anti-H... | 18 Years - | Universitair Ziekenhuis Brussel | |
| Pamiparib and Low Dose Temozolomide In Patients With Platinum Sensitive Biliary Tract Cancer | NCT04796454 | Platinum-Sensit... | Cisplatin Gemcitabine Oxaliplatin Pamiparib Temozolomide | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors | NCT04450732 | HER2-positive B... HER2-positive B... HER2-Positive S... HER2-Positive A... | GQ1001 | 18 Years - | GeneQuantum Healthcare (Suzhou) Co., Ltd. | |
| Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer | NCT05239169 | Biliary Tract C... Intrahepatic Ch... Hilar Cholangio... Distal Cholangi... Gall Bladder Ca... | Durvalumab Tremelimumab Capecitabine | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations | NCT04579380 | Uterine Neoplas... Uterine Cervica... Biliary Tract N... Urologic Neopla... Carcinoma, Non-... HER2 Mutations ... | tucatinib trastuzumab fulvestrant | 18 Years - | Seagen Inc. | |
| XmAb20717 in Advanced Biliary Tract Cancers | NCT05297903 | Biliary Tract C... | XmAb20717 | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| AssesSment of Early-deteCtion basEd oN liquiD Biopsy in Biliary Tract Cancer (ASCEND-BTC) | NCT05667350 | Biliary Tract C... | Blood drawing Blood drawing | 40 Years - 75 Years | Eastern Hepatobiliary Surgery Hospital | |
| Parenteral Nutrition in Patients With Biliopancreatic Mass Lesions | NCT02670265 | Weight Loss Pancreatic Canc... Biliary Tract C... | Olimel Peri 2.5... Isotonic fluid ... | 18 Years - | University Medicine Greifswald | |
| Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) | NCT04203160 | Biliary Tract C... | CPI 613 Gemcitabine Cisplatin | 18 Years - | University of Michigan Rogel Cancer Center | |
| Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer | NCT06255262 | Biliary Tract C... | Surufatinib Durvalumab | 18 Years - | China Medical University, China | |
| Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer | NCT06282575 | Biliary Tract C... HER2 Gene Mutat... | Zanidatamab Cisplatin Gemcitabine Pembrolizumab Durvalumab | 18 Years - | Jazz Pharmaceuticals | |
| A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer | NCT04837508 | Advanced or Met... | MRG002 | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| Milademetan in Advanced/Metastatic Solid Tumors | NCT05012397 | Solid Tumors Head and Neck C... Cholangiocarcin... Sarcoma Lung Adenocarci... Bladder Urothel... Stomach Adenoca... Breast Cancer I... Ovarian Carcino... Cervical Cancer Non Small Cell ... Gastric Cancer Biliary Tract C... Melanoma Pancreas Cancer MDM2 Gene Ampli... Testicular Germ... Adrenocortical ... | RAIN-32 | 18 Years - | Rain Oncology Inc | |
| The Efficacy and Safety of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract Adenocarcinoma | NCT03830606 | Biliary Tract C... | Nab-paclitaxel,... | 18 Years - 70 Years | ChineseAMS | |
| Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy | NCT04722133 | HER2 Positive A... | HERZUMA+mFOLFOX | 19 Years - | Yonsei University | |
| Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCs | NCT03311789 | Biliary Tract C... | PD-1 inhibitor ... | 18 Years - 75 Years | Chinese PLA General Hospital | |
| A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer | NCT02711553 | Biliary Tract C... Metastatic Canc... Advanced Cancer | Ramucirumab Merestinib Cisplatin Gemcitabine Placebo Oral Placebo IV | 18 Years - | Eli Lilly and Company | |
| NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer | NCT04005339 | Advanced Biliar... | Nanoliposomal I... Leucovorin Fluorouracil | 18 Years - | Georgetown University | |
| Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment | NCT05170438 | Advanced Biliar... | Lenvatinib Pill... | 20 Years - | National Health Research Institutes, Taiwan | |
| A Phase I Study of Adjuvant Chemotherapy With GC in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy | NCT01297998 | Biliary Tract C... | gemcitabine , c... | 20 Years - | Kansai Hepatobiliary Oncology Group | |
| Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study | NCT03110484 | Biliary Tract C... | Pemetrexed 500 ... Erlotinib | 20 Years - | Samsung Medical Center | |
| An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC | NCT05327582 | Pancreatic Canc... Biliary Tract C... | Durvalumab Lenvatinib Nab paclitaxel | 18 Years - 75 Years | Chinese PLA General Hospital | |
| Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma | NCT02128282 | Cholangiocarcin... | CX-4945 Cisplatin Gemcitabine | 18 Years - | Senhwa Biosciences, Inc. | |
| Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) | NCT05451043 | Pancreatic Canc... Hepatocellular ... Biliary Tract C... Cholangiocarcin... | Durvalumab Gemcitabine Nab paclitaxel Tremelimumab Propranolol Cisplatin | 18 Years - | AHS Cancer Control Alberta | |
| Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer | NCT04561453 | Biliary Tract C... Cholangiocarcin... Gallbladder Can... Intrahepatic Ch... Perihilar Chola... Extrahepatic Ch... Hilar Cholangio... Distal Bile Duc... | Multi-Platform ... | 18 Years - | University of Washington | |
| Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer | NCT04163900 | Biliary Tract C... | NUC-1031 Gemcitabine Cisplatin | 18 Years - | NuCana plc | |
| RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2 | NCT05417230 | Biliary Tract C... | RC48-ADC Envafolimab | 18 Years - | Jiangsu Cancer Institute & Hospital | |
| Phase I Study of Gemcitabine or S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer | NCT01291615 | Biliary Tract C... | Gemcitabine S-1 | 20 Years - | Kansai Hepatobiliary Oncology Group | |
| Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer | NCT04333927 | Biliary Tract C... Extrahepatic Ch... Gallbladder Can... | Chemotherapy Observation Immunotherapy Radiotherapy | 18 Years - 70 Years | Sun Yat-sen University | |
| A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2) | NCT04907851 | Advanced Solid ... | RXC004 RXC004 RXC004 Denosumab pembrolizumab | 18 Years - | Redx Pharma Plc | |
| Second Line Therapy in Advanced Biliary Tract Cancer | NCT01530503 | Biliary Tract C... | capecitabine an... Capecitabine | 18 Years - 75 Years | IRCCS San Raffaele | |
| Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC | NCT02992340 | Biliary Tract C... | Varlitinib Cisplatin Gemcitabine | - | ASLAN Pharmaceuticals | |
| Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer | NCT00361231 | Biliary Tract C... Gallbladder Ade... | Bevacizumab Gemcitabine Oxaliplatin | 18 Years - | Massachusetts General Hospital | |
| A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases | NCT04338685 | Carcinoma, Hepa... Biliary Tract C... Secondary Liver... Liver Metastase... | RO7119929 Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC) | NCT06320301 | Biliary Tract C... Gemox Chemother... | Adebrelimab + G... | - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy | NCT04722133 | HER2 Positive A... | HERZUMA+mFOLFOX | 19 Years - | Yonsei University | |
| Case Series Study of Biliary Tract Cancer Patients in Japan | NCT01294085 | Biliary Tract C... | 20 Years - | Kansai Hepatobiliary Oncology Group | ||
| Observational Study on Patients With Hepatobiliary Tumors | NCT04637048 | Hepatocellular ... Cholangiocarcin... Gallbladder Can... Biliary Tract C... Gastric Cancer Colorectal Canc... | 18 Years - | First Affiliated Hospital of Wenzhou Medical University | ||
| Irinotecan, Gemcitabine, Chemotherapy for Biliary Tract Cancer | NCT00832689 | Biliary Tract C... | Irinotecan and ... | 17 Years - 75 Years | Yonsei University | |
| Storage of Bile From Routine Procedures to Study Risk Factors | NCT00414843 | Gallbladder Can... Cholangiocarcin... Biliary Tract C... | 18 Years - | Indiana University | ||
| A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma | NCT00881504 | Biliary Tract C... | "Bevacizumab" i... | 18 Years - | Georgetown University | |
| A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors | NCT03314935 | Biliary Tract C... Colorectal Canc... Endometrial Can... Gastroesophagea... Ovarian Cancer Solid Tumors | INCB001158 Oxaliplatin Leucovorin 5-Fluorouracil Gemcitabine Cisplatin Paclitaxel | 18 Years - | Incyte Corporation | |
| Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer | NCT00123825 | Gallbladder Can... Biliary Tract C... | Gemcitabine Cisplatin | 18 Years - | Dana-Farber Cancer Institute | |
| ctDNA Detection of MRD in Predicting Postoperative Recurrence in Biliary Tract Cancers：A Multicenter Prospective Trial | NCT05743959 | Biliary Tract C... | No intervention | 18 Years - | The First Affiliated Hospital with Nanjing Medical University | |
| Endoluminal Radiofrequency Ablation for the Treatment of Malignant Biliary Stenosis | NCT04801719 | Radiofrequency ... Biliary Tract C... Stent Complicat... Brachytherapy | Habib™ EndoHPB;... | 18 Years - | Brno University Hospital | |
| SHR-1210 in Combination With GEMOX in Patients With Advanced BTC | NCT03486678 | Biliary Tract C... Cholangiocarcin... | SHR-1210+GEMOX | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody | NCT05994001 | Biliary Tract C... Candonilimab Claudin 18.2 | cardonilizumab LM-302 | 18 Years - | Shanghai Zhongshan Hospital | |
| Monitoring of patIents With Microdialysis Following Pancreaticoduodenectomy | NCT03631173 | Pancreatic Canc... Pancreatic Neop... Biliary Tract C... Duodenal Cancer Pancreatic Fist... | Surgical og rad... | 18 Years - | Oslo University Hospital | |
| Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) | NCT05771480 | Biliary Tract C... | Durvalumab Gemcitabine mon... Gemcitabine + c... Gemcitabine + o... Gemcitabine + c... Gemcitabine + c... Gemcitabine + S... Gemcitabine + c... | 18 Years - 130 Years | AstraZeneca | |
| Pembrolizumab in Biliary Tract Cancer | NCT03260712 | Biliary Tract C... Metastatic Canc... Advanced Cancer Gallbladder Can... | Pembrolizumab Cisplatin Gemcitabine | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
